CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

AZN Inks Deal With Dizal to In-License Rights to Lung Cancer Drug

PartnershipPositive
AI Analysis

Summary

AstraZeneca has entered into a licensing agreement with Dizal to in-license rights to a lung cancer drug candidate. The deal represents a strategic partnership to expand AZN's oncology portfolio.

Importance:6/10
Sentiment:
0.50
in-licensinglung cancerpartnershipdrug development
Related Companies

Read the original article

Published by yahoo_finance on July 15, 2026 4:04 PM

Read Original